Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.79 |
| ▸ | HTT | P42858 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.54 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.54 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.53 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.51 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.51 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL61095 | 1.00 | PDPK1 (0.79) | PDPK1HTTLMNAALDH1A1TAS1R3 | |
| SCHEMBL29453898 | 1.00 | PDPK1 (0.79) | PDPK1HTTLMNAALDH1A1TAS1R3 | |
| SCHEMBL30142522 | 1.00 | PDPK1 (0.79) | PDPK1HTTLMNAALDH1A1TAS1R3 | |
| SCHEMBL61094 | 1.00 | PDPK1 (0.79) | PDPK1HTTLMNAALDH1A1TAS1R3 | |
| Hydrochloric Acid SCHEMBL31126266 | 0.98 | PDPK1 (0.76) | PDPK1HTTLMNAALDH1A1TAS1R3 | |
| Hydrochloric Acid SCHEMBL5795775 | 0.98 | PDPK1 (0.76) | PDPK1HTTLMNAALDH1A1TAS1R3 | |
| SCHEMBL2465738 | 0.88 | PDPK1 (1.00) | PDPK1ADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL61508 | 0.88 | PDPK1 (1.00) | PDPK1ADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL14612385 | 0.88 | PDPK1 (1.00) | PDPK1ADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL61509 | 0.88 | PDPK1 (1.00) | PDPK1ADRA2AADRA2BADRA2CADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024145483-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CANCER AND METHODS OF MAKING AND USING THE SAME | HTG MOLECULAR DIAGNOSTICS, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| US-20230192606-A1 | DIRECT THROMBIN INHIBITORS AND METHODS OF USE THEREOF | BAYLOR COLLEGE OF MEDICINE (US) | 2023-06-22 | — | — | US | disclosed |
| US-20230192606-A1 | DIRECT THROMBIN INHIBITORS AND METHODS OF USE THEREOF | BAYLOR COLLEGE OF MEDICINE (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2021211913-A1 | DIRECT THROMBIN INHIBITORS AND METHODS OF USE THEREOF | BAYLOR COLLEGE OF MEDICINE (US) | 2021-10-21 | — | — | WO | disclosed |
| US-20180044343-A1 | BICYCLIC IMIDAZOLO DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-02-15 | — | — | US | disclosed |
| US-9365614-B2 | IAP BIR domain binding compounds | PHARMASCIENCE INC. (CA) | 2016-06-14 | — | — | US | disclosed |
| EP-2434889-B1 | IAP INHIBITORS | TETRALOGIC BIRINAPANT UK LTD (GB) | 2016-03-09 | — | — | EP | disclosed |
| US-20140336134-A1 | IAP BIR Domain Binding Compounds | PHARMASCIENCE INC. (CA) | 2014-11-13 | — | — | US | disclosed |
| EP-2170848-B1 | PYRAZINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF LUNG DISEASES | ASTRAZENECA AB (SE) | 2014-10-22 | — | — | EP | disclosed |
| US-8765681-B2 | IAP BIR domain binding compounds | PHARMASCIENCE INC. (CA) | 2014-07-01 | — | — | US | disclosed |
| US-20040158067-A1 | 3-substituted-6-aryl pyridines | NEUROGEN CORPORATION | 2004-08-12 | — | — | US | disclosed |
| WO-2004043925-A2 | 3-SUBSTITUTED-6-ARYL PYRIDINED AS LIGANDS OF C5A RECEPTORS | NEUROGEN CORPORATION (US) | 2004-05-27 | — | — | WO | disclosed |
| EP-1198463-A2 | COMPOUNDS FOR USE IN TREATMENT OF NEUROLOGICAL DISORDERS | AstraZeneca UK Limited (GB) | 2002-04-24 | — | — | EP | disclosed |
| EP-1140852-A1 | 1,2,3,4-TETRAHYDRONAPHTHALENES AND THEIR PHARAMACEUTICAL USE | AstraZeneca AB (SE) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000078751-A2 | COMPOUNDS FOR USE IN TREATMENT OF NEUROLOGICAL DISORDERS | ASTRAZENECA UK LIMITED (GB) | 2000-12-28 | — | — | WO | disclosed |
| WO-2000035882-A1 | 1,2,3,4-TETRAHYDRONAPHTHALENES AND THEIR PHARMACEUTICAL USE | ASTRAZENECA AB (SE) | 2000-06-22 | — | — | WO | disclosed |
| US-5463126-A | Process for preparing sertraline | PFIZER INC. (US) | 1995-10-31 | — | — | US | disclosed |
| EP-0594666-B1 | PROCESS FOR PREPARING SERTRALINE | PFIZER LTD (GB) | 1995-09-13 | — | — | EP | disclosed |
| WO-1993001162-A1 | PROCESS FOR PREPARING SERTRALINE | PFIZER LIMITED (GB) | 1993-01-21 | — | — | WO | disclosed |
| US-5082970-A | Process for recycling amine isomer | PFIZER INC. (US) | 1992-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192606-A1 | DIRECT THROMBIN INHIBITORS AND METHODS OF USE THEREOF | TFPI, TFPI2, PLAT | PDPK1 1707/4885HTT 2964/4885LMNA 967/4885 |
| US-20180044343-A1 | BICYCLIC IMIDAZOLO DERIVATIVE | PDE3A, PDE2A, PDE5A | PDPK1 110/4885HTT 4781/4885LMNA 2416/4885 |
| US-20140336134-A1 | IAP BIR Domain Binding Compounds | BIRC2, BIRC7, BIRC5 | PDPK1 2590/4885HTT 2559/4885LMNA 505/4885 |
| US-20040158067-A1 | 3-substituted-6-aryl pyridines | C3AR1, C5AR1, C5AR2 | PDPK1 2612/4885HTT 4549/4885LMNA 3866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.